Publications by authors named "K Howarth"
There is a lack of biomarkers to predict outcome following initial treatment in patients with high-grade ovarian cancer. We hypothesized that monitoring mutation () in circulating tumor DNA (ctDNA) could be a tumor-specific biomarker. Patients enrolled in a prospective study (NCT03010124) consented to analysis of biological samples through the disease course.
View Article and Find Full Text PDFTo control and optimize the power of the SPARC tokamak, we require information on the total radiated power of the plasma and its 2D and 3D spatial distribution. The SPARC bolometry diagnostic is being designed and built to measure the radiated power for controlling power balance, investigating the dissipation capabilities of various divertor concepts, and measuring the efficacy of the disruption thermal load mitigation. Proven resistive bolometer sensor technology will be used, with 248 lines of sight integrated into pinhole cameras in 20 different locations.
View Article and Find Full Text PDFBackground: Cardiopulmonary bypass (CPB) is associated with hemolysis and acute kidney injury (AKI). The study aim was to determine if urine dipstick blood in infants after CPB was associated with AKI and urine neutrophil gelatinase-associated lipocalin (NGAL).
Methods: Infants who underwent CPB at a single center were enrolled prospectively between October 2017 and June 2019.
Article Synopsis
- Direct current cardioversion (DCCV) is a procedure used to treat atrial fibrillation, and a study compared follow-up methods between remote photoplethysmography (PPG) and traditional 12-lead electrocardiograms (ECG).
- The analysis involved 416 patients, showing high compliance rates for both methods, but PPG was more cost-effective, saving money and travel time for patients while also reducing carbon emissions.
- Ultimately, the study concluded that remote PPG monitoring is a practical alternative for post-DCCV arrhythmia follow-up, with no safety concerns reported.
Background: Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAF-mutant NSCLC.
Methods: CTCs and cfDNA were examined in seven BRAF-mutant NSCLC patients at failure to treatment.